Imugene sees positive early signals in Phase 1 VAXINIA study
–News Direct– Imugene Ltd (ASX:IMU) (OTCMKTS:IUGNF) CEO Leslie Chong talks Proactive through a clinical trial update of its Phase 1 MAST (Metastatic Advanced Solid Tumours) trial evaluating the safety and efficacy of novel cancer-killing virus CF33-hNIS (VAXINIA). Chong says the early positive response data being